1 clinical trials found.
-
AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)
If you are the parent or guardian of a child/adolescent diagnosed with acute lymphoblastic leukemia, your child may qualify to participate in a clinical ...
